American Association for Cancer Research
Browse

Supplementary Table S7 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets

Download (3.31 MB)
dataset
posted on 2025-09-04, 07:20 authored by Vindhya Vijay, Negin Karisani, Lei Shi, Yu-Han Hung, Phuong Vu, Prabhat Kattel, Lauren Kenney, Joshua Merritt, Ramzi Adil, Qibiao Wu, Yuanli Zhen, Robert Morris, Johannes Kreuzer, Meena Kathiresan, Xcanda Ixchel Herrera Lopez, Haley Ellis, Ilaria Gritti, Lilian Lecorgne, Ines Farag, Alexandra Popa, William Shen, Hiroyuki Kato, Qin Xu, Eranga R. Balasooriya, Meng-Ju Wu, Jinkai Wan, Hiroshi Kondo, Saireudee Chaturantabut, Srivatsan Raghavan, Matthew D. Hall, Samarjit Patnaik, Min Shen, Robin K. Kelley, James M. Cleary, Michael S. Lawrence, David E. Root, Krushna C. Patra, Vanessa S. Silveira, Cyril H. Benes, Vikram Deshpande, Dejan Juric, William R. Sellers, Cristina R. Ferrone, Wilhelm Haas, Francisca Vazquez, Gad Getz, Nabeel Bardeesy
<p>Excel file containing all data corresponding to Figure 6</p>

Funding

TargetCancer Foundation

Cholangiocarcinoma Foundation

DOD Peer Reviewed Cancer Research Program (PRCRP)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

Related Materials

  1. 1.
    DOI - Is supplement to Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets

ARTICLE ABSTRACT

Biliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report integrative analysis of 63 BTC cell lines via multi-omics and genome-scale CRISPR screens. We identify widespread EGFR dependency in BTC, alongside dependencies selective to anatomic subtypes. Additionally, we delineate strategies to overcome therapeutic resistance, with combined EGFR inhibition potentiating targeting of KRAS-mutant and FGFR2 fusion–driven models and SHP2 inhibition effective in the latter context. Clustering RNA/protein expression and dependencies data revealed functional relationships transcending single-gene alterations, with biliary, squamous, or dual biliary/hepatocyte lineage signatures stratifying BTC models. These subtypes exhibit distinct dependency profiles—including cell fate transcription factors GRHL2, TP63, and HNF1B, respectively—and demonstrate prognostic significance in patient samples. Potential subtype-specific targetable vulnerabilities include integrinα3 and the detoxification enzyme UXS1. This cell line atlas reveals therapeutic targets in molecularly defined BTCs, unveils disease subtypes, and provides a resource for therapeutic development. This integrative analysis of BTC cell lines defines the landscape of vulnerabilities across BTCs, stratifying distinct subtypes, and provides a key resource for studying disease heterogeneity. The findings highlight strategies for targeting BTCs with specific genomic alterations, as well as broader approaches based on shared molecular programs and essential pathways.

Usage metrics

    Cancer Discovery

    Categories

    Keywords

    Genome BiologyComparative transcriptomics

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC